摘要:
A transgenic non-human mammal whose germ cells and somatic cells contain a constructively activated tyrosine kinase receptor introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammals can be used as ligand-independent in vivo models for the identification and development of selective tyrosine kinase modulators for the treatment of cancer.
摘要:
Methods for increasing endothelial cell apoptosis under hypoxic conditions in a patient undergoing a treatment that comprises an IGF1R inhibitor, the method comprising administering to the patient a VEGFR2 inhibitor
摘要:
IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
摘要:
IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.